Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study

Fig. 4

Kaplan–Meier curve comparing the progression-free survival of 28 patients who received pembrolizumab with chemotherapy as first-line therapy stratified according to PD-L1 expression status as high (≥ 50%; n = 9) and low (< 50%; n = 19)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us